Athira Pharma (NASDAQ:LONA – Get Free Report) posted its earnings results on Monday. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.27), Zacks reports.
Athira Pharma Stock Down 12.7%
LONA stock opened at $3.03 on Tuesday. The company has a market cap of $28.46 million, a P/E ratio of -0.72 and a beta of 1.90. Athira Pharma has a twelve month low of $2.21 and a twelve month high of $14.21. The business has a fifty day moving average of $5.26 and a 200-day moving average of $7.52.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the stock. Citizens Jmp decreased their price objective on shares of Athira Pharma from $17.00 to $16.00 and set a “market outperform” rating on the stock in a research note on Tuesday. Wall Street Zen upgraded Athira Pharma to a “hold” rating in a report on Saturday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Athira Pharma in a research note on Wednesday, November 4th. Finally, Mizuho cut their price target on Athira Pharma from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday, August 19th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Athira Pharma has an average rating of “Moderate Buy” and a consensus price target of $17.00.
View Our Latest Research Report on LONA
About Athira Pharma
Athira Pharma is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair. The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis.
Featured Stories
- Five stocks we like better than Athira Pharma
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
